In studies in which Roferon-A was administered three times a week for 12 months 12% of the patients experienced a sustained response to therapy. Of these patients, 9% maintained this sustained response during continuous follow-up for up to four years.
Roferon, produced by Hoffman-LaRoche, has US FDA approval for use as treatment for hepatitis C since 1996. It has been modified to produce Pegasys, an improved “time-release” treatment that is injected once a week. (See Part III.1.2).
Roferon may be effective in non-responders to other interferon products.
